Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Carcinoma, Renal Cell 32Sarcoma 29Neoplasm Metastasis 17Ovarian Neoplasms 10Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Kidney Neoplasms 6Recurrence 5Lung Neoplasms 5Liposarcoma 5Thyroid Neoplasms 4Melanoma 4Leiomyosarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Pancreatic Neoplasms 3Neurofibrosarcoma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Chondrosarcoma, Extraskeletal Myxoid 3Advanced Cancers 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solitary Fibrous Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2

Interventions

Imatinib Mesylate 32regorafenib 9Sunitinib 9Laparoscopy 5Dasatinib 4Blood Specimen Collection 4pazopanib 3nilotinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Observation 3spartalizumab 2ripretinib 2envafolimab 2binimetinib 2apatinib 2Temozolomide 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2CTLA-4 Antigen 2Biopsy, Fine-Needle 2Biopsy 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Stromal Tumors × pazopanib × Clear all
NCT02342600 2017-10-12

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Sarcoma Alliance for Research through Collaboration

Phase 2 Withdrawn
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01524848 2017-05-10

PAGIST

Scandinavian Sarcoma Group

Phase 2 Completed
72 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01391611 2017-04-07

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Stanford University

Phase 2 Terminated
25 enrolled 7 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡